期刊
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
卷 66, 期 2, 页码 125-132出版社
SPRINGER BASEL AG
DOI: 10.1007/s00005-017-0481-7
关键词
STING; Type I interferons; Innate immunity; Cancer immunology; Cyclic dinucleotides
类别
资金
- National Science Centre (NCN) [PRELUDIUM 9 2015/17/N/NZ6/04260, SONATA BIS 3 2013/10/E/NZ5/00778]
Stimulator of interferon genes (STING) is an adaptor protein that plays an important role in the activation of type I interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response. Therefore, STING agonists are now being extensively developed as a new class of cancer therapeutics. However, little is known about the consequences of activated STING-mediated signaling in cancer cells on the efficacy of the antitumor treatment. It has been shown that activation of the STING-dependent pathway in cancer cells can result in tumor infiltration with immune cells and modulation of the anticancer immune response. Understanding the function of STING pathway in cancer cells might provide important insights into the development of effective therapeutic strategies. This review focuses on the role of STING pathway in cancer cells, the largely unknown topic that has recently emerged to be important in the context of STING-mediated antitumor responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据